BioMarin Pharma (BMRN) Tops Q2 EPS by 18c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $56.50 +1.07%
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.07, $0.18 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $501.7 million versus the consensus estimate of $448.79 million.
GUIDANCE:
BioMarin Pharma sees FY 2021 revenue of $1.75-1.85 billion, versus the consensus of $1.82 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Nike names former Pfizer CFO David Denton as new finance chief
- Stifel Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
